Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
2022
2021
2020
Relapsed/Refractory Follicular Lymphoma
PET/CT Imaging in Prostate Cancer Patients
NTRK
Gene Fusions
Ovarian Cancer Series
NTRK Gene Fusions
Real-World Management of Thyroid Cancer with TRK Inhibitors
By
Ezra Cohen, MD, FRCPSC, FASCO
;
Mary Jo Fidler, MD
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Mary Fidler of Rush University Medical Center, Chicago, IL, recount their clinical experiences and the journeys of patients treated with TRK inhibitors for thyroid cancer.
Read More ›
NTRK Gene Fusions
Real-World Experience with TRK Inhibitors in Patients with Lung and Colon Cancers
By
Ezra Cohen, MD, FRCPSC, FASCO
;
Mary Jo Fidler, MD
;
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Mary Fidler of Rush University Medical Center, Chicago, IL, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, describe their practical experiences with TRK inhibitors in patients with lung cancer and colorectal cancer.
Read More ›
NTRK Gene Fusions
Distinctions and Parallels Among TRK Inhibitors
By
Ezra Cohen, MD, FRCPSC, FASCO
;
Mary Jo Fidler, MD
;
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explore the mutual and contrasting features of TRK inhibitors.
Read More ›
NTRK Gene Fusions
NTRK Gene Fusion Enrichment in Patient Subpopulations
By
Ezra Cohen, MD, FRCPSC, FASCO
;
Mary Jo Fidler, MD
;
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, identify specific subpopulations of patients in which
NTRK
gene fusions may be commonly uncovered.
Read More ›
NTRK Gene Fusions
Occurrence of TRK Fusion–Positive Tumors in Different Cancer Types
By
Ezra Cohen, MD, FRCPSC, FASCO
;
Mary Jo Fidler, MD
;
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, confer on the categorization of various cancer types in which
NTRK
gene fusions may be detected.
Read More ›
NTRK Gene Fusions
Significance of Early and Broad Testing of Tumor Mutations
By
Ezra Cohen, MD, FRCPSC, FASCO
;
Mary Jo Fidler, MD
;
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss how testing for tumor mutations early and broadly may lead to better treatment outcomes.
Read More ›
NTRK Gene Fusions
Who Should Be Screened for Tumor Mutations?
By
Ezra Cohen, MD, FRCPSC, FASCO
;
Mary Jo Fidler, MD
;
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, examine who should be tested for tumor mutations.
Read More ›
Ovarian Cancer Series
An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their support for the use of PARP inhibitors as maintenance therapy in ovarian cancer, and that the optimization of this therapy requires further research to discover the best therapeutic combinations that will be personalized based on patient characteristics.
Read More ›
Ovarian Cancer Series
Immunotherapy in Combination with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, consider the current and future use of immunotherapy, either alone or in combination with other agents such as PARP inhibitors, as first-line maintenance therapy in ovarian cancer.
Read More ›
Ovarian Cancer Series
Adverse Events and Improvements in Quality of Life Associated with First-Line Maintenance Therapy in Ovarian Cancer
By
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, describe the impact that first-line maintenance therapy has on quality of life in patients with ovarian cancer despite adverse events associated with the treatment, and that frequent communication with the healthcare team during maintenance therapy is critical.
Read More ›
Page 3 of 5
1
2
3
4
5
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes